Bambuterol Hcl

證據等級: L5

預測適應症: 0 個

Bambuterol HCL: Drug Repurposing Evaluation — No Active Prediction Available

One-Sentence Summary

Bambuterol HCL is a long-acting beta-2 adrenoceptor agonist prodrug (of terbutaline), historically used in the management of bronchial asthma and chronic obstructive pulmonary disease (COPD). The TxGNN model was unable to generate a repurposing prediction for this drug at this time — the predicted_indications array in the current evidence pack is empty. No clinical trial, literature, or mechanistic evidence can therefore be evaluated for a new indication at this stage.

Quick Overview

Item	Content
Original Indication	Asthma / COPD (historical use; no active UK marketing authorisation on record)
Predicted New Indication	Not available
TxGNN Prediction Score	Not available
Evidence Level	L5 — Model prediction pipeline incomplete; no candidate generated
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why Is a Prediction Not Yet Available?

The evidence pack was returned with an empty predicted_indications array, meaning the TxGNN knowledge graph and deep learning pipeline did not produce a scored repurposing candidate for Bambuterol HCL. This is most likely because a DrugBank ID (drugbank_id: null) could not be resolved for this drug entry, which is a prerequisite for mapping the compound into the TxGNN knowledge graph. Without a valid node in the graph, neither knowledge graph traversal nor the deep learning model can generate a prediction.

Detailed mechanism of action data is also absent from the evidence pack. Based on published pharmacology, bambuterol HCL is a carbamate prodrug that undergoes plasma and tissue hydrolysis to release terbutaline, a selective β₂-adrenoceptor agonist. Its bronchodilatory effects are mediated through cyclic AMP-dependent smooth muscle relaxation in the airways. Whether this mechanism might support repurposing into adjacent disease areas (e.g., premature labour, hyperkalaemia, or inflammatory airway conditions) cannot be formally assessed without a model-generated candidate and supporting evidence data.

Resolving the DrugBank identifier and re-running the prediction pipeline is therefore the critical first step before any repurposing evaluation can proceed.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: This evidence pack contains no TxGNN-predicted indications, no UK marketing authorisations, no DrugBank identifier, and no mechanism of action data — the minimum inputs required for a meaningful drug repurposing evaluation are not yet in place.

To proceed, the following is needed:

Resolve DrugBank ID: Match “BAMBUTEROL HCL” to its canonical DrugBank entry (likely DB01223 via its active metabolite terbutaline; verify the prodrug entry directly) to enable knowledge graph node mapping
Re-run TxGNN pipeline: Once the DrugBank ID is confirmed, execute scripts/run_kg_prediction.py and the deep learning model to generate scored repurposing candidates
Retrieve MOA data: Query the DrugBank API for pharmacodynamics, mechanism, and drug class categorisation
Obtain MHRA safety data: Download the SmPC to populate key warnings, contraindications, and drug interaction profiles
Confirm UK regulatory history: Check the MHRA Public Assessment Report (PAR) register for any historic or revoked product licences (Bambec was previously marketed in the UK as a once-daily tablet and may have a revoked PL on record)
Re-submit Evidence Pack: Once the above data gaps (DG001, DG002) are remediated, resubmit for a full evaluation report
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.